Glenview Trust co Sells 4,109 Shares of Becton, Dickinson and Company (NYSE:BDX)

Glenview Trust co lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,873 shares of the medical instruments supplier’s stock after selling 4,109 shares during the quarter. Glenview Trust co’s holdings in Becton, Dickinson and Company were worth $16,079,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Wesbanco Bank Inc. grew its stake in Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after buying an additional 48 shares during the last quarter. S.A. Mason LLC grew its position in shares of Becton, Dickinson and Company by 3.7% in the fourth quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock valued at $321,000 after purchasing an additional 50 shares during the last quarter. Americana Partners LLC increased its stake in shares of Becton, Dickinson and Company by 3.5% in the fourth quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock worth $345,000 after purchasing an additional 52 shares during the period. Picton Mahoney Asset Management lifted its position in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 54 shares during the last quarter. Finally, Novare Capital Management LLC boosted its stake in Becton, Dickinson and Company by 5.2% during the 4th quarter. Novare Capital Management LLC now owns 1,110 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 55 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 700 shares of the company’s stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total value of $159,593.00. Following the sale, the director now owns 36,033 shares of the company’s stock, valued at approximately $8,215,163.67. This represents a 1.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael David Garrison sold 2,838 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the transaction, the executive vice president now directly owns 6,141 shares of the company’s stock, valued at $1,371,469.53. This represents a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,363 shares of company stock valued at $1,676,105 in the last 90 days. 0.36% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Barclays lifted their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, March 5th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $278.29.

Becton, Dickinson and Company Trading Up 1.6 %

Shares of BDX stock opened at $226.43 on Friday. The firm has a fifty day moving average of $232.78 and a 200-day moving average of $232.33. The stock has a market cap of $65.02 billion, a price-to-earnings ratio of 37.61, a P/E/G ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has authorized a stock repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.84%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.